257 related articles for article (PubMed ID: 30931929)
1. Iron-dependent CDK1 activity promotes lung carcinogenesis via activation of the GP130/STAT3 signaling pathway.
Kuang Y; Guo W; Ling J; Xu D; Liao Y; Zhao H; Du X; Wang H; Xu M; Song H; Wang T; Jing B; Li K; Hu M; Wu W; Deng J; Wang Q
Cell Death Dis; 2019 Apr; 10(4):297. PubMed ID: 30931929
[TBL] [Abstract][Full Text] [Related]
2. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1/STAT3 mutations.
Chen J; Zhang Y; Petrus MN; Xiao W; Nicolae A; Raffeld M; Pittaluga S; Bamford RN; Nakagawa M; Ouyang ST; Epstein AL; Kadin ME; Del Mistro A; Woessner R; Jaffe ES; Waldmann TA
Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3975-3980. PubMed ID: 28356514
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-6 promotes proliferative vitreoretinopathy by inducing epithelial-mesenchymal transition via the JAK1/STAT3 signaling pathway.
Chen X; Yang W; Deng X; Ye S; Xiao W
Mol Vis; 2020; 26():517-529. PubMed ID: 32818015
[TBL] [Abstract][Full Text] [Related]
4. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas.
Gao SP; Mark KG; Leslie K; Pao W; Motoi N; Gerald WL; Travis WD; Bornmann W; Veach D; Clarkson B; Bromberg JF
J Clin Invest; 2007 Dec; 117(12):3846-56. PubMed ID: 18060032
[TBL] [Abstract][Full Text] [Related]
5. STAT3 is required for IL-6-gp130-dependent activation of hepcidin in vivo.
Pietrangelo A; Dierssen U; Valli L; Garuti C; Rump A; Corradini E; Ernst M; Klein C; Trautwein C
Gastroenterology; 2007 Jan; 132(1):294-300. PubMed ID: 17241879
[TBL] [Abstract][Full Text] [Related]
6. JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling.
Song L; Rawal B; Nemeth JA; Haura EB
Mol Cancer Ther; 2011 Mar; 10(3):481-94. PubMed ID: 21216930
[TBL] [Abstract][Full Text] [Related]
7. TRAF2 and TRAF5 associated with the signal transducing receptor gp130 limit IL-6-driven transphosphorylation of JAK1 through the inhibition of proximal JAK-JAK interaction.
Kimura M; Nagashima H; Okuyama Y; Ishii N; So T
Int Immunol; 2018 Jun; 30(7):291-299. PubMed ID: 29668931
[TBL] [Abstract][Full Text] [Related]
8. Deregulated Stat3 signaling dissociates pulmonary inflammation from emphysema in gp130 mutant mice.
Ruwanpura SM; McLeod L; Miller A; Jones J; Vlahos R; Ramm G; Longano A; Bardin PG; Bozinovski S; Anderson GP; Jenkins BJ
Am J Physiol Lung Cell Mol Physiol; 2012 Apr; 302(7):L627-39. PubMed ID: 22268122
[TBL] [Abstract][Full Text] [Related]
9. Raloxifene inhibits pancreatic adenocarcinoma growth by interfering with ERβ and IL-6/gp130/STAT3 signaling.
Pozios I; Seel NN; Hering NA; Hartmann L; Liu V; Camaj P; Müller MH; Lee LD; Bruns CJ; Kreis ME; Seeliger H
Cell Oncol (Dordr); 2021 Feb; 44(1):167-177. PubMed ID: 32940862
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer.
Xu S; Grande F; Garofalo A; Neamati N
Mol Cancer Ther; 2013 Jun; 12(6):937-49. PubMed ID: 23536726
[TBL] [Abstract][Full Text] [Related]
11. Blockade of the IL-6 trans-signalling/STAT3 axis suppresses cachexia in Kras-induced lung adenocarcinoma.
Miller A; McLeod L; Alhayyani S; Szczepny A; Watkins DN; Chen W; Enriori P; Ferlin W; Ruwanpura S; Jenkins BJ
Oncogene; 2017 May; 36(21):3059-3066. PubMed ID: 27893707
[TBL] [Abstract][Full Text] [Related]
12. Growth-suppressive activity of raloxifene on liver cancer cells by targeting IL-6/GP130 signaling.
Wang Y; Ma H; Zhao C; Liu T; Yan D; Jou D; Li H; Zhang C; Lü J; Li C; Lin J; Li S; Lin L
Oncotarget; 2017 May; 8(20):33683-33693. PubMed ID: 28430601
[TBL] [Abstract][Full Text] [Related]
13. Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression.
Schaper F; Gendo C; Eck M; Schmitz J; Grimm C; Anhuf D; Kerr IM; Heinrich PC
Biochem J; 1998 Nov; 335 ( Pt 3)(Pt 3):557-65. PubMed ID: 9794795
[TBL] [Abstract][Full Text] [Related]
14. STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor.
Wang Y; van Boxel-Dezaire AH; Cheon H; Yang J; Stark GR
Proc Natl Acad Sci U S A; 2013 Oct; 110(42):16975-80. PubMed ID: 24082147
[TBL] [Abstract][Full Text] [Related]
15. Tetraspanin CD9 stabilizes gp130 by preventing its ubiquitin-dependent lysosomal degradation to promote STAT3 activation in glioma stem cells.
Shi Y; Zhou W; Cheng L; Chen C; Huang Z; Fang X; Wu Q; He Z; Xu S; Lathia JD; Ping Y; Rich JN; Bian XW; Bao S
Cell Death Differ; 2017 Jan; 24(1):167-180. PubMed ID: 27740621
[TBL] [Abstract][Full Text] [Related]
16. Evidence that IL-6-type cytokine signaling in cardiomyocytes is inhibited by oxidative stress: parthenolide targets JAK1 activation by generating ROS.
Kurdi M; Booz GW
J Cell Physiol; 2007 Aug; 212(2):424-31. PubMed ID: 17385713
[TBL] [Abstract][Full Text] [Related]
17. Sepsis induces interleukin 6, gp130/JAK2/STAT3, and muscle wasting.
Zanders L; Kny M; Hahn A; Schmidt S; Wundersitz S; Todiras M; Lahmann I; Bandyopadhyay A; Wollersheim T; Kaderali L; Luft FC; Birchmeier C; Weber-Carstens S; Fielitz J
J Cachexia Sarcopenia Muscle; 2022 Feb; 13(1):713-727. PubMed ID: 34821076
[TBL] [Abstract][Full Text] [Related]
18. NEK9, a novel effector of IL-6/STAT3, regulates metastasis of gastric cancer by targeting ARHGEF2 phosphorylation.
Lu G; Tian S; Sun Y; Dong J; Wang N; Zeng J; Nie Y; Wu K; Han Y; Feng B; Shang Y
Theranostics; 2021; 11(5):2460-2474. PubMed ID: 33500736
[No Abstract] [Full Text] [Related]
19. Partial inhibition of gp130-Jak-Stat3 signaling prevents Wnt-β-catenin-mediated intestinal tumor growth and regeneration.
Phesse TJ; Buchert M; Stuart E; Flanagan DJ; Faux M; Afshar-Sterle S; Walker F; Zhang HH; Nowell CJ; Jorissen R; Tan CW; Hirokawa Y; Eissmann MF; Poh AR; Malaterre J; Pearson HB; Kirsch DG; Provero P; Poli V; Ramsay RG; Sieber O; Burgess AW; Huszar D; Vincan E; Ernst M
Sci Signal; 2014 Sep; 7(345):ra92. PubMed ID: 25270258
[TBL] [Abstract][Full Text] [Related]
20. Repositioning Bazedoxifene as a novel IL-6/GP130 signaling antagonist for human rhabdomyosarcoma therapy.
Xiao H; Bid HK; Chen X; Wu X; Wei J; Bian Y; Zhao C; Li H; Li C; Lin J
PLoS One; 2017; 12(7):e0180297. PubMed ID: 28672024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
